University of Virginia

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Virginia sits in the top decile of US sponsors by registered trial count (#78 of 15,742 sponsors by registered trial count).

449 total trials 101 currently recruiting 281 completed early-phase tilt top decile by trial count

University of Virginia: 449 sponsored US clinical trials, 101 recruiting.

University of Virginia sponsors 449 registered US clinical trials on ClinicalTrials.gov, 101 of them currently recruiting, and 281 completed. 40 of these trials are in Phase 3-4 (later-stage) and 109 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 1 Diabetes Mellitus, with 9 trials.

Top-decile sponsor footprint

University of Virginia ranks in the top decile of sponsors by registered trial count (#78 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 61/100

281 of 317 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

449 total, page 3 of 9

RECRUITING Early Phase 1

Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

NCT00929006

ACTIVE NOT RECRUITING

Perfusion Abnormalities in Hypertrophic Cardiomyopathy

NCT06599229

ACTIVE NOT RECRUITING NA

Feasibility of Delivering VergeRx at FQHCs

NCT06161675

ACTIVE NOT RECRUITING NA

iSIPsmarter: A Pilot RCT to Evaluate a Web-based Behavioral Intervention to Reduce Sugary Beverages Among Black Adults

NCT06184737

ACTIVE NOT RECRUITING Phase 4

Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients

NCT05514847

ACTIVE NOT RECRUITING NA

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

NCT05370469

ACTIVE NOT RECRUITING Phase 1

Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL

NCT03962465

ACTIVE NOT RECRUITING NA

Development of UP2UTobacco for High School Youth

NCT05396911

ACTIVE NOT RECRUITING Phase 1

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

NCT03240211

ACTIVE NOT RECRUITING Phase 2

The Use of Memantine for Prevention of Alzheimer's Disease

NCT05063851

ACTIVE NOT RECRUITING

Imaging Sodium and Lymphatics in Lymphedema

NCT05242900

ACTIVE NOT RECRUITING NA

The R-CITY Project: A Collaborative Intervention With Teachers and Youth

NCT05585918

ACTIVE NOT RECRUITING

Visualizing Vascular Mechanisms of Lipedema

NCT05464927

ACTIVE NOT RECRUITING Phase 2

Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

NCT04482894

ACTIVE NOT RECRUITING NA

Low Intensity Shockwave Therapy for Erectile Dysfunction

NCT04434352

ACTIVE NOT RECRUITING NA

Lymphocyte Depletion and Change in Lymphocyte Functionality

NCT04273893

ACTIVE NOT RECRUITING Phase 2

Advanced Immunoclinical Phenotyping of Rejection in Lung Transplant

NCT03697395

ACTIVE NOT RECRUITING Phase 1

Her2-BATS and Pembrolizumab in Metastatic Breast Cancer

NCT03272334

ACTIVE NOT RECRUITING Phase 2

Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics

NCT03002389

ACTIVE NOT RECRUITING Phase 1

BATs Treatment for Pancreatic Cancer, Phase Ib/II

NCT03269526

ACTIVE NOT RECRUITING

HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy

NCT01915615

NOT YET RECRUITING NA

VergeRx for Smokers Not Ready to Quit

NCT07693660

NOT YET RECRUITING NA

Feasibility of a Medical-Legal Partnership Model to Connect Coal Miners QuitAid

NCT07694492

NOT YET RECRUITING Phase 3

The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)

NCT07298915

NOT YET RECRUITING Early Phase 1

MCE Molecular Imaging for ICI Myocarditis

NCT07538544

NOT YET RECRUITING NA

A Pre-post Pilot of a Smartphone Intervention

NCT07665346

NOT YET RECRUITING NA

Evaluating a Decision Aid for Sentinel Lymph Node Biopsy in Intermediate-Risk Melanoma

NCT07653087

NOT YET RECRUITING Early Phase 1

Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI

NCT05880355

NOT YET RECRUITING Phase 4

Effect of Local Anesthetic Concentration on Rebound Pain: A Randomized Control Study

NCT07146685

NOT YET RECRUITING

Validation of a Portable Ankle Arthrometer

NCT07163897

NOT YET RECRUITING NA

Inorganic Nitrate as a Treatment for ANOCA: NO-ANOCA

NCT06948201

COMPLETED

Smartphone-based Utility of the Vestibulo-ocular Reflex

NCT06856746

COMPLETED NA

InsuLearn Feasibility With Type 1 Diabetes Patients Under MDI Therapy

NCT06411548

NOT YET RECRUITING

Cell-Surface Plectin in the Diagnosis of Cholangiocarcinoma from ERCP-directed Biliary Samples

NCT06651346

COMPLETED Phase 2

Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease

NCT06903910

COMPLETED NA

Evaluating the Anticancer Learning Circle Lifestyle Program in Endometrial Cancer Survivors

NCT06550791

COMPLETED NA

Automated Insulin Delivery (AID) for Basal Insulin Titration in Type 2 Diabetes

NCT06024928

COMPLETED NA

Effects of Foot Rehabilitation And Minimalist Shoes on Pain, Strength, and Function in Adults With Plantar Fasciopathy

NCT06106958

COMPLETED NA

Pharmacokinetics of Berkeley Life Oral Nitrate Supplementation

NCT06777108

COMPLETED NA

Optical Measurements of the Skin Surface to Infer Distinctions in Myofascial Tissue Stiffness

NCT06390085

COMPLETED

Integrated Predictive Monitoring for Sepsis and Necrotizing Enterocolitis

NCT07254559

COMPLETED NA

The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.

NCT06111508

COMPLETED NA

Neural-net Artificial Pancreas (NAP)

NCT05876273

COMPLETED NA

The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies

NCT05786014

COMPLETED NA

Low-Intensity Focused Ultrasound for Cocaine Use Disorder

NCT05857852

TERMINATED NA

Exercise Preconditioning with Cancer Surgeries

NCT04923672

COMPLETED NA

Fruit and Vegetable Intake in Preschoolers

NCT05730530

COMPLETED

Hiatal Hernia and Pulmonary Involvement

NCT05716022

COMPLETED Phase 2

Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy

NCT05605301

COMPLETED

mMe: Motivational Monitoring to Enhance Smoking Cessation Among Cancer Patients

NCT05370859

← Previous Page 3 of 9 Next →

Phase Distribution

PhaseTrial count
Phase 1 58
Phase 2 51
Phase 3 14
Phase 4 26

What is open in the University of Virginia pipeline

101 recruiting of 449 indexed (22% open); 281 completed (63%).

Phase mix: 40 late (III/IV) vs 109 early (I/II) (early-phase heavy).

Top condition: Type 1 Diabetes Mellitus (9 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Virginia: open-pipeline peers nationwide

Peers matched on 449 registered trials and 22% open enrollment, not the therapeutic-area sidebar.

University of Virginia sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 5%10%15%20%25% Total trials Recruiting share University of VirginiaMedical College of WisconsinAlliance for Clinical Trials in OncologyBoston Children's HospitalChildren's Hospital of PhiladelphiaOhio State University Comprehensive Cancer CenterUniversity of DelawareUniversity of OklahomaALX Oncology
University of Virginia sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Virginia sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 449 trials (± recruiting share)

Sponsors near 22% open enrollment (± trial volume)

What to do with this University of Virginia page

449 registered trials is a research-attention snapshot, not an endorsement of University of Virginia or any single study.

  • 101 of University of Virginia's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Type 1 Diabetes Mellitus is the condition University of Virginia studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 1 Diabetes Mellitus trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Virginia pipeline card: 449 registered trials from official public datasets.Report a data error.